Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Dairy diet may boost brain function in overweight adults

NCT ID NCT07355309

Knowledge-focused Sponsor: Maastricht University Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether eating 4-5 servings of dairy foods daily (like milk, cheese, and yogurt) can improve brain function and thinking skills in overweight adults aged 40-75. Participants will be randomly assigned to a high-dairy or low-dairy diet for several weeks. Researchers will measure brain blood flow, insulin sensitivity, memory, and gut bacteria to understand how dairy affects the gut-brain connection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2025

An estimate. Start dates often move.

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Men and postmenopausal women (≥ 2 years since last menstruation); * Aged between 40-75 years; * BMI between 25-35 kg/m2 (overweight or obese); * Low-to-moderate habitual dairy consumption (≤ 3 servings/day); * Fasting serum total cholesterol \< 8.0 mmol/L; * Fasting serum triacylglycerol \< 4.5 mmol/L; * Fasting plasma glucose \< 7.0 mmol/L; * Systolic blood pressure \< 160 mmHg and diastolic blood pressure \< 100 mmHg; * Stable body weight (weight gain or loss \< 3 kg in the past three months). Exclusion Criteria: * Left-handedness; * Milk protein allergy or lactose intolerance; * Current smoker, or smoking cessation \< 12 months; * Familial hypercholesterolemia; * Abuse of drugs; * Alcoholic intake \>3 standard drinks/day; * Use of medications, food products or dietary supplements affecting glucose, lipid, or blood pressure regulation, gut microbiota or mental or neurological function, judged by the principal investigator; * Use of antibiotics within the previous month; * Use of other biomedical investigational products within the previous month; * Participation in another clinical trial within the past month; * Severe medical conditions including type 2 diabetes, epilepsy, asthma, kidney failure, COPD, inflammatory bowel disease, autoimmune diseases, or rheumatoid arthritis; * History of cardiovascular events (e.g., heart attack, stroke) or active cardiovascular disease; * Contra-indications for MRI imaging (e.g. pacemaker, metal implants, claustrophobia); * Willing to donate blood starting from 8 weeks before the study begins, throughout the study, and for 4 weeks after its inclusion; * Difficult to venipuncture as evidenced during the screening visit.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Appetite control are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Appetite control Brain insulin sensitivity Brain vascular function Cerebral blood flow Cognitive performance Gut microbiota

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Maastricht University

    Maastricht, Limburg, 6229ER, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.